Guggenheim cuts ArriVent BioPharma target to $18
Guggenheim cut its ArriVent BioPharma price target to $18.00 per share from $45.00, according to Benzinga.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.